Articles related to Pain Medicine

A GLP-1 receptor agonist delivered directly into the knee joint received FDA Fast Track designation for osteoarthritis with synovitis, with phase 2a data not expected until 2027.

“At the end of the day, it’s vital to avoid overuse of opioids—when the harms would outweigh the benefits—but also to avoid underuse.” – Cary P. Gross, MD, Professor of Medicine at YSM

“Basically women were told: ‘You’re lucky to be alive. Some pain is expected. Suck it up and deal with it.'” — Dr. Sean Mackey, Stanford University Pain Medicine

The FDA notice added that a letter was sent out about the recall. However, it did not include a press release or other specific details.

“The key word is association. This study does not establish causality. For absolute, catastrophic harm to an appropriately selected, monitored pain patient, the risk is small.” – Sean Mackey, MD, PhD, Chief of the Division of Stanford Pain Medicine

“The more frequently the brain is exposed to migraine attacks, the more likely it is to become sensitized…early intervention is critical.” – Dr. Andrew Blumenfeld, Director of the San Diego Headache Center and The Los Angeles Headache Center San Diego/Los Angeles.